Growth Hormone Secretagogues
GHRH analogues (CJC-1295, sermorelin, tesamorelin) and ghrelin mimetics (ipamorelin, hexarelin, GHRPs).
-
IGF-1 LR3: benefits, evidence and legal status
IGF-1 LR3 (Long R3 IGF-1) is an 83-amino-acid recombinant analogue of human insulin-like growth factor 1, developed as a research reagent, whose evidence so far comes only from lab and…
-
AOD-9604 (hGH fragment 176-191): six obesity trials, safety and regulatory history
AOD-9604 is a synthetic 16-amino-acid fragment of human growth hormone (hGH 177-191 plus an extra tyrosine), developed in Australia as an oral anti-obesity drug. It is not approved by the…
-
GHRP-2 and GHRP-6: benefits, evidence and legal status
GHRP-2 (pralmorelin) and GHRP-6 are synthetic six-amino-acid growth hormone-releasing peptides that act on the ghrelin receptor. Neither is FDA approved; GHRP-2 is approved in Japan only as a one-time diagnostic…
-
Sermorelin: benefits, evidence and legal status
Sermorelin is a synthetic 29-amino-acid copy of the active start of human growth hormone-releasing hormone (GHRH) that signals the pituitary to release growth hormone; its strongest evidence is a former…
-
CJC-1295 with and without DAC (Mod GRF 1-29): how they differ, studies and FDA votes
CJC-1295 is a synthetic 29-amino-acid analog of growth hormone-releasing hormone (GHRH) that makes the pituitary release more growth hormone; its original form carries a “DAC” albumin-binding tag that makes one…
-
Ipamorelin: growth hormone studies, the bowel-surgery trial, FDA vote and WADA ban
Ipamorelin is a synthetic five-amino-acid peptide (a pentapeptide) that copies the action of ghrelin to make the pituitary gland release growth hormone, developed by Novo Nordisk in the 1990s as…
-
Tesamorelin (Egrifta): benefits, evidence and legal status
Tesamorelin is a synthetic 44-amino-acid analog of human growth hormone-releasing hormone (GHRH), made by Theratechnologies and sold in the US as Egrifta SV and Egrifta WR. It is FDA-approved for…